Digital Health And Pharma Still Defining Rules Of Engagement
Pharma is still searching for how to best bring digital therapeutics on board
Despite all of the buzz around adoption of digital health tools and whopping VC investments in consumer-facing digital health firms, pharma has yet to articulate a business model for co-development or integration of behavior-modifying digital therapeutics into their portfolios.
You may also be interested in...
Biogen and Happy Health announced a pilot partnership to evaluate Happify Health’s Kopa app to support people living with multiple sclerosis. This follows a licensing deal with digital therapeutics developer MedRhythms to support MS patients with gait deficit.
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.